Protocol Ledger

NCT07230119 · Phase III · ACTIVE NOT RECRUITING

A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

Interventional Phase III clinical trial protocol NCT07230119 sponsored by Beijing QL Biopharmaceutical Co in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-16 Enrollment: 755 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07230119
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)755 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07230119
Protocol FieldVerified Registry Value
NCT IdentifierNCT07230119
Consolidated Lead SponsorBeijing QL Biopharmaceutical Co
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment755 participants (ACTUAL)
Registered Start Date2026-01-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07230119
Hospital Research SiteLocationSite Profile
Beijing Friendship Hospital , Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI